Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study
Diabetes, Obesity and Metabolism · 2026-06 · 28 (6) · 5058-5067
DOI: 10.1111/dom.70701 ↗At a glance
Multizentrische Studie in Diabetes, Obesity and Metabolism, published online on 2026-03-24. Written by Taweesak Wannachalee and 6 co-authors. Institution: Division of Endocrinology and Metabolism, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk, Chiang Mai University.
Topics: Diabetes mellitus
Abstract (original language)
Aims
The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real‐world clinical settings. Materials and Methods This retrospective, multi‐centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023. Eligible participants had no prior injectable therapy and completed at least 26 weeks of treatment. The primary endpoint was the change in HbA1c from baseline to the end‐of‐study (EoS, Week 26); Week 52 outcomes were exploratory. Secondary endpoints included changes in body weight and the proportion achieving HbA1c < 7%. Severe hypoglycaemia was the safety endpoint. A post hoc composite endpoint combined HbA1c < 7% with ≥ 3% weight loss. Analyses used a mixed model for repeated measures and descriptive statistics.
Results
Oral semaglutide was predominantly used as add‐on therapy (190/195 [97.4%]). Mean HbA1c decreased by −0.7% (95% CI: −0.9 to −0.5; p < 0.0001), and the mean body weight decreased by −4.3 kg (95% CI: −5.5 to −3.2; p < 0.0001). At the EoS, 75.9% (117/154) achieved an HbA1c < 7%, and 57.7% (71/123) met the composite endpoint. No severe hypoglycaemia occurred. Dose escalation from 3 mg to 14 mg was observed in 53.2% by Week 26 and 70.4% by Week 52.
Conclusions
The REALISED study provides the first real‐world evidence of the use of oral semaglutide in Thai patients with T2D, demonstrating significant improvements in glycaemic control and weight reduction across routine care settings.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Endocrinology and Metabolism, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Endocrinology and Metabolism Unit, Department of Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
- Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
- Novo Nordisk Pharma Thailand Ltd., Bangkok, Thailand.
- Section of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID profiles: Supawan Buranapin
Funding
- Novo Nordisk
- Chiang Mai University
Cite
APA
Wannachalee, T., Anthanont, P., Sirisreetreerux, S., Nayak, G., Chumchujan, W., Iamsudjai, Y., & Buranapin, S. (2026). Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study. Diabetes, Obesity and Metabolism, 28(6), 5058-5067. https://doi.org/10.1111/dom.70701
Vancouver
Wannachalee T, Anthanont P, Sirisreetreerux S, Nayak G, Chumchujan W, Iamsudjai Y, et al. Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study. Diabetes, Obesity and Metabolism. 2026;28(6):5058-5067. doi:10.1111/dom.70701
BibTeX
@article{Wannachalee2026,
author = {Wannachalee, Taweesak and Anthanont, Pimjai and Sirisreetreerux, Supamas and Nayak, Gurudutt and Chumchujan, Woralak and Iamsudjai, Yodying and Buranapin, Supawan},
title = {Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {6},
pages = {5058--5067},
doi = {10.1111/dom.70701}
}
EUVIMED